SPPI Stock Overview
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Spectrum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$0.32 |
| Beta | 2.14 |
| 1 Month Change | 4.54% |
| 3 Month Change | -1.90% |
| 1 Year Change | 17.05% |
| 3 Year Change | -71.39% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.25% |
Recent News & Updates
Recent updates
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 14
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates
May 12Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
Sep 20Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
Sep 16Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection
Sep 09Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'
Aug 21Spectrum Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Jun 04Spectrum Pharmaceuticals: Some Last Words
Feb 25Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Oct 05Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Aug 12Spectrum's Big Approval: Any Day Now
Jul 29FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS
Jun 01Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
May 31We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
Feb 12Spectrum Pharma drops after announcing less-than-favorable Phase 2 data
Dec 22Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like
Dec 21Spectrum Pharma Is Down But Not Out
Nov 16Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib
Nov 11Shareholder Returns
| SPPI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | -0.3% | -2.7% |
| 1Y | 17.0% | 7.5% | 13.1% |
Return vs Industry: SPPI exceeded the US Biotechs industry which returned 8.6% over the past year.
Return vs Market: SPPI exceeded the US Market which returned 10.4% over the past year.
Price Volatility
| SPPI volatility | |
|---|---|
| SPPI Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: SPPI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SPPI's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 86 | Tom Riga | https://www.sppirx.com |
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations.
Spectrum Pharmaceuticals, Inc. Fundamentals Summary
| SPPI fundamental statistics | |
|---|---|
| Market Cap | US$209.89m |
| Earnings (TTM) | -US$67.71m |
| Revenue (TTM) | US$25.73m |
8.2x
P/S Ratio-3.1x
P/E RatioIs SPPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPPI income statement (TTM) | |
|---|---|
| Revenue | US$25.73m |
| Cost of Revenue | US$2.86m |
| Gross Profit | US$22.87m |
| Other Expenses | US$90.58m |
| Earnings | -US$67.71m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.90% |
| Net Profit Margin | -263.16% |
| Debt/Equity Ratio | 107.6% |
How did SPPI perform over the long term?
See historical performance and comparison